This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy

< Back

AT406 (Debio 1143) for Ovarian Cancer – neoadjuvant therapy


Cancer and Palliative Care

January 2018

Ovarian cancer is the sixth most common cancer in women in the UK. The ovaries are a pair of small organs located in the lower abdomen and are part of the female reproductive system. Usually women who have been through menopause and aged 65 years and over are more likely to be affected by ovarian cancer. The exact cause is not known but most cases are caused by gene changes that develop during a woman’s life and are not inherited. The main treatment options for ovarian cancer are surgery and chemotherapy. Most patients with ovarian cancer are diagnosed at an advanced stage and have a combination of both surgery and chemotherapy. Chemotherapy may be prescribed before and/or after surgery. Chemotherapy before surgery is called ‘neoadjuvant chemotherapy’.
AT406 is a medicine under development to be added to standard neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. AT406 is a small molecule that induces cancer cell death through a dual mode of action. If licensed, AT406 may offer an additional neoadjuvant treatment option for patients with epithelial ovarian cancer especially those who develop drug resistance and relapse to other standard chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts